Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Except for historical information contained herein, this news release
contains forward-looking statements that are subject to risks and
uncertainties. Factors that could affect these forward-looking statements
include, but are not limited to, market demand for the Company's
securities, pricing and other terms related to the sale of the notes, the
efficacy of PROVENGE to treat men suffering from prostate cancer, risks and
uncertainties surrounding the presentation of data to the FDA and approval
of product applications by the FDA and risks and uncertainties inhe
|SOURCE Dendreon Corporation|
Copyright©2007 PR Newswire.
All rights reserved